selective RORgt inverse agonist
entered clinical dev. (psoriasis), discontinued
from HTS and SBDD
ACS Med. Chem. Lett., Apr. 10, 2020
Bristol Myers Squibb, Princeton, NJ
BMS-986251
BMS-986251 is an inverse agonist of RORgt, a hot target in inflammation for a significant period. Unfortunately it looks like development hit a wall in this space, and several publications…